Illumina

Meet the MiSeq i100 Series – the new standard in sequencing simplicity with a 3-step setup, onboard DRAGEN analysis, and same-day results to accelerate genomic discovery and insights: https://bit.ly/4eTqugz

Our recent acquisition of Fluent BioSciences is set to transform single-cell research. In our latest article, Cande Rogert and Soroush Zarandi, PhD, MBA discuss how PIPseq V simplifies workflows and brings high-throughput applications to every lab. Dive into the details and see how we’re making cutting-edge technology accessible to all: https://bit.ly/4f8rBcL. And if you’re attending #ASHG24, don’t miss our talk on the power of PIPseq V in scRNA-Seq!

Build a mini MiSeq i100 Series with us! Do you want to see the MiSeq i100 Series and maybe get a mini model of your own? Stop by our booth at #ASHG24!

For IT Director Suresh Gadamsetti, Diwali this year is extra special. It’s the first time in nearly two decades he’ll celebrate the festival of lights back in India, surrounded by family and his community. Learn more about Suresh’s journey back to India and what #Diwali means to him: https://bit.ly/4fovauV #IlluminaProud

Thanks to our employees around the globe who participated in the Illumina Cares #StepsAgainstCancer campaign throughout October in support of organizations dedicated to fighting cancer. The campaign concluded this weekend with the Making Strides Against Cancer event in San Diego. We are honored to have been the presenting sponsor and have our CCO, Everett Cunningham, speak about our ongoing dedication to oncology innovation and research.    Learn more about how employees came together for this great cause: https://bit.ly/4e2Rzgx

Curious about what's new in the MiSeq i100 Series? Our Chief Technology Officer, Steven Barnard, deep dives on our latest sequencing innovation.

Why are countries racing to develop nationwide sequencing programs? The short answer: To address country-specific health needs. The Human Genome Project provided the first (almost) complete reference genome, but it didn’t say much about human variation. For that, scientists had to conduct massive population genomics (pop gen) studies, sequencing millions of people to better understand the genetic distinctions, in specific populations, that confer good health or disease. Learn about the emerging population genomics revolution and how it benefits us all: https://bit.ly/3UoxCtj

Our #DRAGEN methods paper in @Naturebiotechnology is finally out! Since the beginning of DRAGEN development, our mission has been to deliver, a comprehensive and accurate genome analysis to match and keep up with the advancement, quality and throughput of Illumina's #sequencing! This new paper in @Naturebiotechnology presents the methods, benchmarks and science behind the DRAGEN multi-genome mapping, the variant callers for SNV, SV, CNV, repeat expansions and the set of specialized callers that DRAGEN offers to genotype and discover variations in genes in medically relevant difficult to map regions. It also describes how DRAGEN scaled to support the UK Biobank and All of Us program, and is able to aggregate hundreds of thousands of gVCF incrementally to support cohort level research. Proud of the work of the DRAGEN team that always strives for excellence, and special thanks to Fritz Sedlazeck, Sairam Behera and the team at Baylor College of Medicine Human Genome Sequencing Center for the special collaboration. https://lnkd.in/gGUu9USC #bioInformatics

I’m excited to share exceptional progress in the field of newborn screening and Illumina’s role in accelerating the adoption of whole genome sequencing to provide earlier detection and improved outcomes for babies born with genetic disease.    Illumina is an active collaborator in Project GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns). GUARDIAN the largest study of its kind and investigates the utility of WGS to identify 255 early onset genetic conditions as compared to 65 conditions currently included in standard newborn screening. This collaboration, initiated in 2022 with Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, the New York State Department of Health, GeneDx and Sanofi, aims to offer expanded WGS-based screening to 100,000 babies from a diverse population.   While the study is ongoing, the promising initial findings were published today in JAMA, Journal of the American Medical Association. GUARDIAN is demonstrating the clear benefit of genomics as a powerful tool to help diagnose genetic disease earlier and treat faster when compared to standard screening and to do so at a time when access to care is more equitable – at birth.    GUARDIAN is a testament to the importance of our work at Illumina, the value we place on collaborating deeply with our customers and the impact we can collectively have on improving human health. #thisisthegenomeera

When it comes to enabling more genomic discoveries with NGS—the simpler, the better. That’s why our R&D teams designed benchtop sequencing systems for every lab, everywhere.